

Detailed Market Potential – By Indication

Product and Indication	US Market	EU Market	Global Market
Xebam/Inborn errors of bile acid synthesis and metabolism	1:50,000 live births	Unknown	Unknown
LivUrso/Gallstone dissolution	~1000	NA	NA
LivUrso/Primary biliary cirrhosis	40.2/100,000 ongoing; 2.7/100,000 new cases per annum	NA	NA
LivUrso/Cystic fibrosis associated liver disease	30,000 ongoing; 2500 new cases per annum	NA	NA
Citrupress IV/Prevention of pediatric pulmonary hypertension secondary to cardiopulmonary bypass	25,000 per annum	28,000 per annum	Unknown
Citrupress IV/Prevention of bronchopulmonary dysplasia (BPD) in very low-birthweight (VLBW) infants	60,000 per annum	65,000 per annum	45,000 per annum (Japan)
Citrupress IV/Treatment of pediatric status asthmaticus	> 500,000 per annum	600,000 per annum	Unknown
Citrupress IV/Prevention of persistent pulmonary hypertension of the newborn (PPHN)	80,000 per annum	88,000 per annum	Unknown
Citrupress IV/Prevention of hepatic veno-occlusive disease (HVOD) in bone marrow transplant recipients	15,000-20,000 per annum	15,000-20,000 per annum	Unknown
Citrupress IV/Prevention of cerebral vasospasm post-subarachnoid hemorrhage	27,000 per annum	Unknown	Unknown